Merseyside Inter Agency Drug Misuse Database

January - March 2009

Liverpool DAAT

Quarter 4 2008/09

**Lloyd Baron, Steven Griffith,
Martin Chandler, Jim McVeigh**

DRAFT REPORT
The final version will be available on the IAD website

www.cph.org.uk/iad

Contacts:
Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
Castle House
North Street
L3 2AY

(0151) 231 4531
m.chandler@ljmu.ac.uk

Lloyd Baron
IAD Researcher

(0151) 231 4521
L.R.Baron@ljmu.ac.uk

www.cph.org.uk/iad

Contents

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

> Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)
Quarter 4 (2008/09)

Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	434	80.1
Female	108	19.9
Age Group		
Under 18	0	0.0
18-19	33	6.1
20-24	93	17.2
25-29	87	16.1
30-34	96	17.7
35-39	106	19.6
40-44	68	12.5
45+	59	10.9
Total	542	100

Table 2: Year to Date, by Gender & Age Group

	Gender					
	Male		Female		*Total in Age Group*	
Age Group	n	%	n	%	*n*	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	115	8.0	13	3.7	128	7.2
20-24	280	19.4	47	13.4	327	18.3
25-29	234	16.3	44	12.6	278	15.5
30-34	219	15.2	72	20.6	291	16.3
35-39	260	18.1	75	21.4	335	18.7
40-44	191	13.3	49	14.0	240	13.4
45+	141	9.8	50	14.3	191	10.7
Total	1,440	100	350	100	1,790	100

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Amphetamines	0	3
Benzodiazepines	9	2
Cannabis	58	22
Crack	108	58
Cocaine	24	61
Ecstasy	0	0
Heroin	182	57
Methadone	34	3
Other	2	3

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where "Main drug" is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the "Main Drug". However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

SYRINGE EXCHANGE SERVICES

Quarter 4 (2008/09)

Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

AGENCY SYRINGE EXCHANGE

Table 4: Individuals by Gender

New Clients	n	%
Male	83	95.4
Female	4	4.6
Total	87	100
All Clients		
Male	362	91.9
Female	32	8.1
Total	394	100

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	21	84.0
Female	4	16.0
Total	25	100
All Clients		
Male	161	85.2
Female	28	14.8
Total	189	100

Table 6: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	3	3.4	4	1.0
20-24	10	11.5	39	9.9
25-29	24	27.6	75	19.0
30-34	15	17.2	77	19.5
35-39	13	14.9	76	19.3
40-44	14	16.1	70	17.8
45+	8	9.2	53	13.5
Total	87	100	394	100

Table 7: Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	1	4.0	4	2.1
25-29	3	12.0	21	11.1
30-34	3	12.0	30	15.9
35-39	5	20.0	45	23.8
40-44	9	36.0	51	27.0
45+	4	16.0	38	20.1
Total	25	100	189	100

Table 8: Gender by Age Group of Individuals

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	4	1.1	0	0.0
20-24	38	10.5	1	3.1
25-29	67	18.5	8	25.0
30-34	67	18.5	10	31.3
35-39	71	19.6	5	15.6
40-44	65	18.0	5	15.6
45+	50	13.8	3	9.4
Total	362	100	32	100

Table 9: Gender by Age Group: Steroid Users omitted

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	3	1.9	1	3.6
25-29	14	8.7	7	25.0
30-34	22	13.7	8	28.6
35-39	40	24.8	5	17.9
40-44	46	28.6	5	17.9
45+	36	22.4	2	7.1
Total	161	100	28	100

Table 10: Year to Date, by Gender & Age Group

Age Group	Male		Female		Total in Age Group	
	n	%	n	%	n	%
Under 18	1	<1	0	0.0	1	<1
18-19	14	1.5	0	0.0	14	1.4
20-24	121	13.0	5	6.7	126	12.5
25-29	181	19.4	11	14.7	192	19.0
30-34	173	18.5	19	25.3	192	19.0
35-39	199	21.3	19	25.3	218	21.6
40-44	149	16.0	11	14.7	160	15.9
45+	95	10.2	10	13.3	105	10.4
Total	933	100	75	100	1,008	100

Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Male		Female		Total in Age Group	
	n	%	n	%	n	%
Under 18	1	<1	0	0.0	1	<1
18-19	1	<1	0	0.0	1	<1
20-24	13	3.3	5	7.0	18	3.9
25-29	33	8.3	10	14.1	43	9.2
30-34	62	15.7	17	23.9	79	16.9
35-39	118	29.8	19	26.8	137	29.3
40-44	102	25.8	11	15.5	113	24.2
45+	66	16.7	9	12.7	75	16.1
Total	396	100	71	100	467	100

Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	20	24.1	4	100
Methadone	0	0.0	0	0.0
Melanotan	0	0.0	0	0.0
Steroids	62	74.7	0	0.0
Other	1	<1	0	0.0
*Total**	83	100	4	100

Table 13: Main Drug of Use for All Agency Syringe Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	1	<1	1	3.1
Heroin	146	40.3	25	78.1
Methadone	7	1.9	0	0.0
Melanotan	1	<1	0	0.0
Steroids	201	55.5	4	12.5
Other	7	1.9	2	6.3
*Total**	363	100	32	100

*Please Note: Totals may not be concurrent due to the reporting of Melanotan clients. Further details are available on request.

Table 14: Main Drug of Use for New Agency Syringe Exchange Clients, by Age Group

Age Group	Ampheta-mine		Benzodi-azepine		Cocaine		Crack		Heroin		Methadone		Steroids	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	-	-	-	-	-	-	-	-	0	0.0	-	-	0	0.0
18-19	-	-	-	-	-	-	-	-	0	0.0	-	-	3	4.8
20-24	-	-	-	-	-	-	-	-	1	4.2	-	-	9	14.5
25-29	-	-	-	-	-	-	-	-	3	12.5	-	-	21	33.9
30-34	-	-	-	-	-	-	-	-	3	12.5	-	-	12	19.4
35-39	-	-	-	-	-	-	-	-	4	16.7	-	-	8	12.9
40-44	-	-	-	-	-	-	-	-	9	37.5	-	-	5	8.1
45+	-	-	-	-	-	-	-	-	4	16.7	-	-	4	6.5
*Total**	-	-	-	-	-	-	-	-	24	100	-	-	62	100

* % Totals are by Drug, not Age Group.

Please Note: Due to a change in reporting methods main drug of use by age group will only be reported for new clients. Information on age group for all clients is available on request.

PHARMACY SYRINGE EXCHANGE

Table 15: Individuals by Gender

New Clients	n	%
Male	912	84.7
Female	165	15.3
Total	1,077	100
All Clients		
Male	1,564	83.6
Female	307	16.4
Total	1,871	100

Table 16: Individuals by Age Group

	New Clients		All Clients	
Age Group	**n**	**%**	**n**	**%**
Under 18	19	1.8	24	1.3
18-19	44	4.1	62	3.3
20-24	108	10.0	170	9.1
25-29	190	17.6	305	16.3
30-34	228	21.2	394	21.1
35-39	243	22.6	460	24.6
40-44	132	12.3	271	14.5
45+	113	10.5	185	9.9
Total	1,077	100	1,871	100

Table 17: Year to Date, by Gender & Age Group

	Gender				Total in Age Group	
	Male		**Female**			
Age Group	**n**	**%**	**n**	**%**	***n***	***%***
Under 18	50	1.0	9	1.0	59	1.0
18-19	165	3.3	15	1.7	180	3.0
20-24	526	10.4	62	7.0	588	9.9
25-29	718	14.2	163	18.4	881	14.8
30-34	1,015	20.1	196	22.1	1,211	20.4
35-39	1,307	25.8	198	22.4	1,505	25.3
40-44	772	15.3	154	17.4	926	15.6
45+	508	10.0	88	9.9	596	10.0
Total	5,061	100	885	100	5,946	100

COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 18: Individuals in Syringe Exchange, by Gender

New Clients	n	%
Male	986	85.5
Female	167	14.5
Total	1,153	100
All Clients		
Male	1,870	85.1
Female	328	14.9
Total	2,198	100

Table 19: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted*

New Clients	n	%
Male	924	84.7
Female	167	15.3
Total	1,091	100
All Clients		
Male	1,669	83.7
Female	324	16.3
Total	1,993	100

*Only known steroid users, based on Agency SES data, have been omitted.

Table 20: Individuals in Syringe Exchange, by Age Group

	New Clients		All Clients	
Age Group	n	%	n	%
Under 18	19	1.6	24	1.1
18-19	47	4.1	66	3.0
20-24	117	10.1	204	9.3
25-29	211	18.3	369	16.8
30-34	240	20.8	456	20.7
35-39	254	22.0	519	23.6
40-44	144	12.5	327	14.9
45+	121	10.5	233	10.6
Total	1,153	100	2,198	100

Table 21: Individuals in Syringe Exchange by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	19	1.7	24	1.2
18-19	44	4.0	62	3.1
20-24	108	9.9	169	8.5
25-29	190	17.4	315	15.8
30-34	228	20.9	409	20.5
35-39	246	22.5	488	24.5
40-44	139	12.7	308	15.5
45+	117	10.7	218	10.9
Total	1,091	100	1,993	100

Table 22: Year to Date, by Gender & Age Group

Age Group	Gender				*Total in Age Group*	
	Male		Female			
	n	%	n	%	*n*	%
Under 18	50	< 1	9	1.0	59	< 1
18-19	179	3.1	13	1.4	192	2.9
20-24	628	10.9	68	7.3	696	10.4
25-29	882	15.3	167	17.9	1,049	15.6
30-34	1,147	19.9	207	22.2	1,354	20.2
35-39	1,434	24.8	208	22.3	1,642	24.5
40-44	870	15.1	164	17.6	1,034	15.4
45+	584	10.1	96	10.3	680	10.1
Total	5,774	100	932	100	6,706	100

Table 23: Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	15,062	100,841	115,903	557,764

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

National Drug Treatment Monitoring System (NDTMS)
Quarter 4 (2008/09)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 24: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	585	74.3
Female	202	25.7
Total	787	100
All Clients		
Male	3,366	71.1
Female	1,367	28.9
Total	4,733	100

Table 25: Year to Date, by Gender

New Clients	n	%
Male	1,808	73.6
Female	647	26.4
Total	2,455	100
All Clients		
Male	3,513	71.0
Female	1,434	29.0
Total	4,947	100

Table 26: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	71	9.0	277	5.9
18-19	16	2.0	77	1.6
20-24	51	6.5	272	5.7
25-29	86	10.9	469	9.9
30-34	137	17.4	895	18.9
35-39	179	22.7	1,237	26.1
40-44	135	17.2	885	18.7
45+	112	14.2	621	13.1
Total	787	100	4,733	100

Table 27: Year to Date, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	212	8.6	314	6.3
18-19	43	1.8	85	1.7
20-24	144	5.9	285	5.8
25-29	254	10.3	494	10.0
30-34	438	17.8	929	18.8
35-39	594	24.2	1,284	26.0
40-44	444	18.1	912	18.4
45+	326	13.3	644	13.0
Total	2,455	100	4,947	100

Table 28: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	719	91.4	4,429	93.6
White Irish	7	<1	31	<1
Other White	3	<1	29	<1
White & Black Caribbean	5	<1	15	<1
White & Black African	2	<1	11	<1
African	3	<1	11	<1
White & Asian	4	<1	7	<1
Other Black	12	1.5	46	1.0
Caribbean	4	<1	7	<1
Chinese	0	0.0	9	<1
Other	18	2.2	67	1.4
Unknown	10	1.3	71	1.5
Total	787	100	4,733	100

Table 29: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	471	59.8	2,993	63.2
Methadone	48	6.1	336	7.1
Other Opiates	15	1.9	53	1.1
Benzodiazepine	2	<1	19	<1
Amphetamines	4	<1	39	<1
Cocaine	97	12.3	575	12.1
Crack	30	3.8	162	3.4
Ecstasy	0	0.0	9	<1
Cannabis	115	14.6	481	10.2
Prescription Drugs	2	<1	8	<1
Other/Unknown	3	<1	58	1.2
Total	787	100	4,733	100

YOUNG ADDACTION OUTREACH
Quarter 4 (2008/09)

Background

Young Addaction provide a confidential support service for young people with substance use issues, advice and guidance are provided along with harm reduction education. Data provided by Young Addaction in Liverpool are shown here.

Table 30: Individuals by Gender

Gender	n	%
Male	6	54.5
Female	5	45.5
Total	11	100

Table 31: Main Drug by Age Group

	Alcohol		Cannabis		Cocaine		Not Stated	
Age Group	n	%	n	%	n	%	n	%
Under 18	1	25.0	1	25.0	1	50.0	1	100
18-24	3	75.0	3	75.0	1	50.0	0	0.0
Total	4	100	4	100	2	100	1	100

Table 32: Individuals Accommodation

Accommodation Type	n	%
Hostel	2	18.2
Housing Association	2	18.2
Parental Home	4	36.4
Private Rented	2	18.2
Supported Housing	1	9.1
Total	11	100

Table 33: Referrals and Interventions

Referral/Intervention Type	n	%
Training & Employment	2	18.2
Treatment Service	2	18.2
Drug Service	1	9.1
BBV Counsellor	2	18.2
Specialist Counselling	1	9.1
Substance Misuse Education	1	9.1
Motivational work	2	18.2
Total	11	100

Table 34: Harm Reduction Advice & Information

Harm Reduction Advice Type	n	%
Abstinence Programmes	1	9.1
Sharing Equipment	2	18.2
Physical/Mental Health	1	9.1
Diet Nutrition	1	9.1
Sexual Risk	1	9.1
Drug Advice	3	27.3
Addaction Details	2	18.2
Total	11	100

CONNEXIONS
Quarter 4 (2008/09)

Background

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

Table 35: Individuals in Contact with Connexions, by Gender

Gender	n	%
Male	75	66.4
Female	38	33.6
Total	113	100

Table 36: Year to Date, by Gender

Gender	n	%
Male	105	60.3
Female	69	39.7
Total	174	100

Table 37: Individuals in Contact with Connexions, by Age

Age Group	n	%
16	16	14.2
17	44	38.9
18	37	32.7
19	16	14.2
Total	113	100

Table 38: Year to Date, by Age

Age Group	n	%
16	31	17.8
17	61	35.1
18	46	26.4
19	36	20.7
Total	174	100

Table 39: Individuals in Contact with Connexions by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	28	24.8
Drugs	85	75.2
Total	113	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

Table 40: Year to Date, by Drug/Alcohol problem

Substance	n	%
Alcohol/Other*	55	31.6
Drugs	119	68.4
Total	174	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

COMBINED DATASETS
Quarter 4 (2008/09)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, Syringe Exchange (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 41: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	5,187	75.5
Female	1,680	24.5
Age Group		
Under 18	341	5.0
18-19	221	3.2
20-24	547	8.0
25-29	840	12.2
30-34	1,288	18.8
35-39	1,663	24.2
40-44	1,138	16.6
45+	829	12.1
Total	6,867	100

Table 42: Year to Date, by Gender and Age Group

	Gender				Total in Age Group	
	Male		Female			
Age Group	n	%	n	%	n	%
Under 18	335	3.4	106	4.4	441	3.6
18-19	426	4.4	73	3.0	499	4.1
20-24	1,110	11.3	189	7.8	1,299	10.6
25-29	1,360	13.9	336	13.9	1,696	13.9
30-34	1,761	18.0	487	20.1	2,248	18.4
35-39	2,255	23.0	569	23.5	2,824	23.1
40-44	1,482	15.1	377	15.6	1,859	15.2
45+	1,063	10.9	280	11.6	1,343	11.0
Total	9,792	100	2,417	100	12,209	100

CROSS-MATCHED DATASETS
Quarter 4 (2008/09)

Data are shown for the crossover between each type of Syringe Exchange and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site.

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets

AGENCY
(394)

138 Male
25 Female

NDTMS
(4,733)

Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

PHARMACY
(1,871)

367 Male
100 Female

NDTMS
(4,733)